Skip to main content
MRMD
OTC Life Sciences

MariMed Q2 10-Q: Record Revenue, Wider Loss, and $7M in Disputed IRS Liens

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.065
Mkt Cap
$25.952M
52W Low
$0.061
52W High
$0.23
52W Position info
6.6% above low
Off High info
72% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

MRMD is trading near its 52-week low of $0.061 (6.6% above the low).

Summary

MariMed reported record Q2 revenue of $41.9M but a wider net loss of $3.6M. The 10-Q also disclosed $7M in disputed IRS tax liens and a $786K tax benefit from cannabis rescheduling.


Key Events · Earnings and Guidance · MRMD

  • Record Revenue, Wider Loss

    Q2 revenue rose 6.1% to $41.9M, but net loss widened to $3.6M from $1.4M a year ago, driven by higher cost of revenue and operating expenses.

  • IRS Tax Liens Total $7M

    The company disclosed IRS liens of approximately $1M against FSC and $6M against the company for prior tax periods, both being disputed through Collection Due Process hearings.

  • Schedule III Tax Benefit

    The DOJ's April 2026 rescheduling of cannabis to Schedule III reduced income tax expense by approximately $786,000 in Q2 2026.

  • Series B Restructuring Completed

    The February 2026 restructuring exchanged $14.2M of Series B obligations for $8M in new notes and 26.9M shares of new preferred stock, recognizing a $0.7M gain.


Analysis · MRMD · Life Sciences

MariMed's Q2 10-Q confirms record revenue of $41.9M but a wider net loss of $3.6M, driven by margin pressure and higher operating costs. The filing reveals $7M in disputed IRS tax liens and a $786K tax benefit from the DOJ's Schedule III reclassification. While the company states it has sufficient cash for the next 12 months, the combination of rising debt, tax disputes, and continued losses keeps pressure on the balance sheet.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MRMD was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $26M. The 52-week trading range was $0.06 to $0.23. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MRMD - Latest Insights

MRMD
Nov 12, 2026, 5:43 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.075
Real-time Price: $0.07028 info
Change: -$0.00472 (-6%) info
Market Cap: $28.375M info
MRMD
Nov 11, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.0745
Real-time Price: $0.07028 info
Change: -$0.00422 (-6%) info
Market Cap: $28.375M info
MRMD
Oct 29, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.053
Real-time Price: $0.07028 info
Change: +$0.01728 (+33%) info
Market Cap: $28.375M info
MRMD
Sep 22, 2026, 4:42 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.0732
Real-time Price: $0.07028 info
Change: -$0.00292 (-4%) info
Market Cap: $28.375M info
MRMD
Sep 11, 2026, 4:06 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.0788
Real-time Price: $0.07028 info
Change: -$0.00852 (-11%) info
Market Cap: $28.375M info